ArticleParasites & vectors2026
Molecular characterization of thioredoxin peroxidases 1 from Trichinella spiralis and its potential in generating protective immunity.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTrichinella spiralis remains a significant food-borne parasitic threat with no licensed vaccine available. This study evaluated the vaccine potential of T. spiralis thioredoxin peroxidase 1 (Ts-TPx1).
methodsRecombinant Ts-TPx1 (rTs-TPx1) was expressed, purified, and characterized. Mice were immunized intraperitoneally with rTs-TPx1 plus ISA206, ISA206 alone, or PBS, and subsequently challenged orally with T. spiralis larvae. Systemic and intestinal immune reponses, protection efficacy, intestianl barrier function, and pathological changes in the murine intestine and diaphragm muscle were subsequently assessed.
resultsTs-TPx1 belongs to the 2-Cys peroxiredoxin family. Native Ts-TPx1 is expressed across key lifecycle stages, predominantly localizing to the parasite surface and stichosome. rTs-TPx1 immunization elevated serum levels of Ts-TPx1-specific IgG, IgG1, and IgG2a, with IgG1 levels higher than IgG2a, and increased splenocyte secretion of specific INF-γ and IL-4. The vaccine conferred significant protection, reducing intestinal adult worm burden by 65.0% and muscle larval burden by 61.8%. It also enhanced intestinal mucosal immunity, as evidenced by increased sIgA and Muc2 levels, and ameliorated intestinal and diaphragm muscle pathology.
conclusionsrTs-TPx1 immunization elicited specific intestinal mucosal immunity and Th2-biased mixed Th1/Th2 systemic protective response, establishing it as a promising vaccine candidate against Trichinella infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.